{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:52:03Z","timestamp":1755795123973,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,16]]},"DOI":"10.7759\/cureus.90262","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T04:30:41Z","timestamp":1755405041000},"source":"Crossref","is-referenced-by-count":0,"title":["Paliperidone as an Alternative Treatment for Behavioral Symptoms in Childhood Autism: Case Report of an Eight-Year-Old Patient"],"prefix":"10.7759","author":[{"given":"Gizem","family":"Keles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal M","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Paliperidone - paliperidone tablet, extended release [package insert]\u00a0U.S. Food and Drug Administration website. (2025). Accessed. 07\/16\/2025: https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/528a962a-4924-4c48-93ce-6ab1f019e52c\/spl-doc?hl=paliperidone."},{"key":"ref2","unstructured":"Aripiprazole - aripiprazole tablet [package insert] U.S. Food and Drug Administration website. (2025). Accessed. 07\/16\/2025: https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/99747897-22fe-4bee-9942-6349c0c8f6b0\/spl-doc?hl=aripiprazole."},{"key":"ref3","unstructured":"Risperidone - risperidone, film coated [package insert] U.S. Food and Drug Administration website. (2025). Accessed. 07\/16\/2025: https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/07d43bf6-a695-453a-a5c7-9581effe585c\/spl-doc?hl=risperidone#S14.4."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara M","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017, 13:2231-41. 10.2147\/NDT.S113099","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008559.pub3","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","volume":"8","author":"Loy JH","year":"2017","unstructured":"Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017, 8:CD008559. 10.1002\/14651858.CD008559.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S49807","article-title":"Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management","volume":"5","author":"Krill RA","year":"2014","unstructured":"Krill RA, Kumra S. Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management. Adolesc Health Med Ther. 2014, 5:171-82. 10.2147\/AHMT.S49807","journal-title":"Adolesc Health Med Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0035","article-title":"Paliperidone palmitate in a child with autistic disorder","volume":"21","author":"Kowalski JL","year":"2011","unstructured":"Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, McDougle CJ. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol. 2011, 21:491-3. 10.1089\/cap.2011.0035","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S84585","article-title":"Aggression in autism spectrum disorder: presentation and treatment options","volume":"12","author":"Fitzpatrick SE","year":"2016","unstructured":"Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat. 2016, 12:1525-38. 10.2147\/NDT.S84585","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-020-04443-1","article-title":"The prevalence of self-injurious behaviour in autism: a meta-analytic study","volume":"50","author":"Steenfeldt-Kristensen C","year":"2020","unstructured":"Steenfeldt-Kristensen C, Jones CA, Richards C. The prevalence of self-injurious behaviour in autism: a meta-analytic study. J Autism Dev Disord. 2020, 50:3857-73. 10.1007\/s10803-020-04443-1","journal-title":"J Autism Dev Disord"},{"key":"ref10","unstructured":"Florida best practice psychotherapeutic medication guidelines for children and adolescents. (2023). Accessed. 07\/21\/2025: https:\/\/floridabhcenter.org\/child-guidelines\/2022-2023-florida-best-practice-psychotherapeutic-medication-guidelines-...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.beth.2019.09.006","article-title":"The internal structure of the aberrant behavior checklist irritability subscale: implications for studies of irritability in treatment-seeking youth with autism spectrum disorders","volume":"51","author":"Stoddard J","year":"2020","unstructured":"Stoddard J, Zik J, Mazefsky CA, DeChant B, Gabriels R. The internal structure of the aberrant behavior checklist irritability subscale: implications for studies of irritability in treatment-seeking youth with autism spectrum disorders. Behav Ther. 2020, 51:310-9. 10.1016\/j.beth.2019.09.006","journal-title":"Behav Ther"},{"key":"ref12","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007, 4:28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref13","unstructured":"Centers for Disease Control and Prevention. Clinical Growth Charts. CDC. (2023). Accessed. 07\/21\/2025: https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0019","article-title":"Paliperidone for irritability in autistic disorder","volume":"20","author":"Stigler KA","year":"2010","unstructured":"Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. 2010, 20:75-8. 10.1089\/cap.2009.0019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2711-3","article-title":"Paliperidone for irritability in adolescents and young adults with autistic disorder","volume":"223","author":"Stigler KA","year":"2012","unstructured":"Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012, 223:237-45. 10.1007\/s00213-012-2711-3","journal-title":"Psychopharmacology (Berl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000500629","article-title":"Paliperidone use in child psychiatry: evidence or diffidence?","volume":"104","author":"Naguy A","year":"2019","unstructured":"Naguy A, Adel T, Almazeedi I.  Paliperidone use in child psychiatry: evidence or diffidence?. Pharmacology. 2019, 104:67-70. 10.1159\/000500629","journal-title":"Pharmacology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken JT","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, et al.. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002, 347:314-21. 10.1056\/NEJMoa013171","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2020.0014","article-title":"Aripiprazole in children and adolescents","volume":"31","author":"Coustals N","year":"2021","unstructured":"Coustals N, M\u00e9nard ML, Cohen D. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. 2021, 31:4-32. 10.1089\/cap.2020.0014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll CU","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302:1765-73. 10.1001\/jama.2009.1549","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-019-0151-7","article-title":"Adverse events associated with risperidone use in pediatric patients: a retrospective biobank study","volume":"6","author":"Oshikoya KA","year":"2019","unstructured":"Oshikoya KA, Carroll R, Aka I, Roden DM, Van Driest SL. Adverse events associated with risperidone use in pediatric patients: a retrospective biobank study. Drugs Real World Outcomes. 2019, 6:59-71. 10.1007\/s40801-019-0151-7","journal-title":"Drugs Real World Outcomes"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011769.pub2","article-title":"Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)","volume":"10","author":"Iffland M","year":"2023","unstructured":"Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023, 10:CD011769. 10.1002\/14651858.CD011769.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents","volume":"70","author":"Singh J","year":"2011","unstructured":"Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011, 70:1179-87. 10.1016\/j.biopsych.2011.06.021","journal-title":"Biol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-024-06372-9","article-title":"Safety and efficacy of paliperidone palmitate in pediatric patients with autism and intellectual disability","author":"Simpson S","year":"2024","unstructured":"Simpson S, Dominick KC, Erickson CA, Lamy M. Safety and efficacy of paliperidone palmitate in pediatric patients with autism and intellectual disability. J Autism Dev Disord. 2024, 10.1007\/s10803-024-06372-9","journal-title":"J Autism Dev Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/361944-paliperidone-as-an-alternative-treatment-for-behavioral-symptoms-in-childhood-autism-case-report-of-an-eight-year-old-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T04:30:47Z","timestamp":1755405047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/361944-paliperidone-as-an-alternative-treatment-for-behavioral-symptoms-in-childhood-autism-case-report-of-an-eight-year-old-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.90262","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}